(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
German foreign minister heads to China to talk rare-earth exports - 2Gym tied to outbreak of obscure disease that spreads through mist
- 3What Yogurt Types Do You Know
- 45 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- 5Climate engineering would alter the oceans, reshaping marine life – our new study examines each method’s risks
- Novo Nordisk gears up for December Ozempic launch in India, sources say
- The race to mine the moon is on – and it urgently needs some clear international rules
- Best Amusement Park Bite: What Do You Very much want to Crunch On?
- Which Kind of Pet Makes the Incomparable Buddy?
- Mating injuries may lead scientists to identify dinosaurs’ sex
- David Duchovny's new thriller has him stripping down at 65. But its chilling premise hits close to home.
- See a half-lit moon shine among the stars of Aquarius on Nov. 27
- Pick Your Number one breakfast food
- Fundamental Home Machines for Improved Solace in Summer
